QIAGEN supplies sample-to-insight molecular technologies used in research labs, clinical diagnostics and the life-science industry. Its core strengths are nucleic-acid extraction and purification kits, assay technologies and automated instruments that prepare biological samples for PCR, sequencing and other molecular tests. Flagship offerings include widely used prep systems and diagnostic assays such as QuantiFERON for latent tuberculosis testing, serving hospitals, public-health labs, pharma and academic researchers.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 533.5 | — | 96.3 | -14.6% |
| Q3 2025 | 532.6 | — | 130 | 11.2% |
| Q4 2025 | 540.4 | — | 107.8 | -15.5% |
| Q1 2026 | 492.3 | — | 68 | -35.1% |
| Q2 2026 | 535 | 0.3% | 103.4 | 7.4% |
All markets — KeepWinning global stock screener
Other companies on DAX: Zalando (ZAL), Scout24 (G24), SAP (SAP), Siemens (SIE), Allianz (ALV), Airbus (AIR)